+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Neoadjuvant (Chemo)radiotherapy With Total Mesorectal Excision Only Is Not Sufficient to Prevent Lateral Local Recurrence in Enlarged Nodes: Results of the Multicenter Lateral Node Study of Patients With Low cT3/4 Rectal Cancer



Neoadjuvant (Chemo)radiotherapy With Total Mesorectal Excision Only Is Not Sufficient to Prevent Lateral Local Recurrence in Enlarged Nodes: Results of the Multicenter Lateral Node Study of Patients With Low cT3/4 Rectal Cancer



Journal of Clinical Oncology 2018: Jco1800032



Improvements in magnetic resonance imaging (MRI), total mesorectal excision (TME) surgery, and the use of (chemo)radiotherapy ([C]RT) have improved local control of rectal cancer; however, we have been unable to eradicate local recurrence (LR). Even in the face of TME and negative resection margins (R0), a significant proportion of patients with enlarged lateral lymph nodes (LLNs) suffer from lateral LR (LLR). Japanese studies suggest that the addition of an LLN dissection (LLND) could reduce LLR. This multicenter pooled analysis aims to ascertain whether LLNs actually pose a problem and whether LLND results in fewer LLRs. Data from 1,216 consecutive patients with cT3/T4 rectal cancers up to 8 cm from the anal verge who underwent surgery in a 5-year period were collected. LLND was performed in 142 patients (12%). MRIs were re-evaluated with a standardized protocol to assess LLN features. On pretreatment MRI, 703 patients (58%) had visible LLN, and 192 (16%) had a short axis of at least 7 mm. One hundred eight patients developed LR (5-year LR rate, 10.0%), of which 59 (54%) were LLRs (5-year LLR rate, 5.5%). After multivariable analyses, LLNs with a short axis of at least 7 mm resulted in a significantly higher risk of LLR (hazard ratio, 2.060; P = .045) compared with LLNs of less than 7 mm. In patients with LLNs at least 7 mm, (C)RT plus TME plus LLND resulted in a 5-year LLR of 5.7%, which was significantly lower than that in patients who underwent (C)RT plus TME (5-year LLR, 19.5%; P = .042). LLR is still a significant problem after (C)RT plus TME in LLNs with a short axis at least 7 mm on pretreatment MRI. The addition of LLND results in a significantly lower LLR rate.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 065856143

Download citation: RISBibTeXText

PMID: 30403572

DOI: 10.1200/jco.18.00032


Related references

Lateral pelvic lymph node dissection after neoadjuvant chemo-radiation for preoperative enlarged lateral nodes in advanced low rectal cancer: study protocol for a randomized controlled trial. Trials 17(1): 561, 2018

Outcomes of Total Mesorectal Excision and Lateral Lymph Node Dissection following Neoadjuvant Chemotherapy for Lower Rectal Cancer with Lateral Lymph Node Metastasis. Gan to Kagaku Ryoho. Cancer & ChemoTherapy 45(13): 1803-1805, 2019

Feasibility of Extended Dissection of Lateral Pelvic Lymph Nodes During Laparoscopic Total Mesorectal Excision in Patients with Locally Advanced Lower Rectal Cancer: A Single-Center Pilot Study After Neoadjuvant Chemotherapy. Medical Science Monitor 24: 3966-3977, 2018

Total mesorectal excision results in low local recurrence rates in lymph node-positive rectal cancer. Diseases of the Colon and Rectum 47(7): 1145-9; Discussion 1149-50, 2004

Total Mesorectal Excision Results in Low Local Recurrence Rates in Lymph Node-Positive Rectal Cancer. Diseases of the Colon & Rectum -1(1): 1, 2004

Factors associated with local recurrence after neoadjuvant chemoradiation with total mesorectal excision for rectal cancer. World Journal of Surgery 33(8): 1741-1749, 2009

Lateral node dissection and total mesorectal excision for rectal cancer. Diseases of the Colon and Rectum 43(10 Suppl.): S59-S68, 2000

Non-inferiority multicenter prospective randomized controlled study of rectal cancer T 2 -T 3s (superficial) N 0 , M 0 undergoing neoadjuvant treatment and local excision (TEM) vs total mesorectal excision (TME). International Journal of Colorectal Disease 33(2): 241-249, 2017

Local recurrence of rectal cancer following total mesorectal excision with or without preoperative radiotherapy. European Surgical Research 32(Suppl 1): 12, 2000

Local recurrence of rectal cancer after total mesorectal excision without preoperative radiotherapy. International Journal of Gastrointestinal Cancer 34(2-3): 129-134, 2004

Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). Journal of Clinical Oncology 30(14): 1620-1627, 2012

Male sexual dysfunction after rectal cancer surgery: Results of a randomized trial comparing mesorectal excision with and without lateral lymph node dissection for patients with lower rectal cancer: Japan Clinical Oncology Group Study JCOG0212. European Journal of Surgical Oncology 42(12): 1851-1858, 2016

Comparative outcome between chemoradiotherapy and lateral pelvic lymph node dissection following total mesorectal excision in rectal cancer. Annals of Surgery 246(5): 754-762, 2007

Outcome in patients with resectable locally recurrent rectal cancer after total mesorectal excision with and without previous neoadjuvant radiotherapy for the primary rectal tumor. Annals of Surgical Oncology 21(2): 520-526, 2014

Clinical feasibility of laparoscopic lateral pelvic lymph node dissection following total mesorectal excision for advanced rectal cancer. Surgery Today 45(3): 310-314, 2015